Diagnosis of Small Intestinal Bacterial Overgrowth (SIBO): An Expert Guide for Automotive Technicians and Beyond

Introduction

Small intestinal bacterial overgrowth (SIBO) is a condition characterized by an excessive amount of bacteria, typically found in the colon, proliferating in the small intestine. Unlike the large intestine, the healthy small intestine maintains a relatively low bacterial concentration, ideally below 1000 organisms per milliliter. This balance is usually upheld by gastric acid secretion and effective intestinal motility. However, when these natural defense mechanisms falter, SIBO can develop, leading to a range of gastrointestinal issues. Similar to how a malfunctioning engine can lead to various diagnostic challenges in automotive repair, SIBO presents a complex clinical picture. This article provides a comprehensive overview of SIBO, focusing on its diagnosis, management, and the importance of an interprofessional approach to patient care. Just as automotive experts at xentrydiagnosis.store excel in diagnosing intricate vehicle problems, understanding SIBO diagnosis is crucial for healthcare professionals dealing with unexplained gastrointestinal symptoms.

Etiology of SIBO

The development of small intestinal bacterial overgrowth is multifactorial. Several categories of factors can contribute, including motility disorders, anatomical abnormalities, immune system deficiencies, reduced gastric acid production (hypochlorhydria), metabolic disorders, and other systemic illnesses.

Several key defense mechanisms normally protect the small intestine from bacterial overgrowth. These include gastric acid and bile, which possess bactericidal properties; peristalsis, the natural intestinal contractions that propel contents forward; digestive enzymes that break down bacteria; a properly functioning ileocecal valve to prevent backflow from the colon; and secretory IgA, an antibody crucial for intestinal immunity. When these protective barriers are compromised, SIBO can ensue. Gastric acid and bile are essential for destroying ingested bacteria and preventing their unchecked proliferation in the intestines. Consequently, conditions leading to achlorhydria (absence of gastric acid) are strongly linked to SIBO.[3] Similarly, proteolytic enzymes play a role in bacterial degradation within the intestines. Chronic pancreatic insufficiency, which reduces digestive enzyme availability, is also a recognized risk factor for SIBO.[3] The migrating motor complex (MMC), responsible for peristalsis, acts as an intestinal housekeeper, clearing the small intestine and preventing bacterial translocation from the colon.[4] Therefore, conditions disrupting gastrointestinal motility, such as irritable bowel syndrome (IBS), narcotic use, post-radiation enteropathy, hypothyroidism, diabetes mellitus, and scleroderma, are frequently associated with SIBO.[3]

Image alt text: Diagram illustrating the various etiologies of Small Intestinal Bacterial Overgrowth (SIBO), including motility disorders, anatomical issues, immune deficiencies, hypochlorhydria, metabolic and systemic disorders.

An intact ileocecal valve, coupled with normal antegrade ileal motility, prevents the reflux of colonic bacteria into the small intestine.[5] Anatomic irregularities within the gastrointestinal tract can create areas of stasis, promoting bacterial overgrowth. These anatomical risk factors include small intestinal diverticulosis, bowel strictures, post-operative adhesions, gastric bypass procedures with resultant blind intestinal loops, and ileocecal valve resection.[3] Finally, secretory immunoglobulin A (IgA), abundant in the gastrointestinal tract, is a critical component of intestinal immunity, preventing bacterial proliferation.[6] Immunodeficiency states, such as acquired immunodeficiency syndrome (AIDS), common variable immunodeficiency, and selective IgA deficiency, are associated with a higher likelihood of developing SIBO.[7]

Epidemiology of SIBO

The precise prevalence of small intestinal bacterial overgrowth remains uncertain. Irritable bowel syndrome, intestinal motility disorders, and chronic pancreatitis are frequently implicated as underlying conditions associated with SIBO, accounting for a significant proportion, estimated at 80-90%, of SIBO cases.[8] SIBO appears to be more common in women and older adults.[9] The incidence of SIBO increases with advancing age, potentially due to age-related reductions in gastric acid production (hypochlorhydria) and impaired intestinal motility. In many instances, individuals with SIBO may have multiple contributing factors identified.

Pathophysiology of SIBO

Small intestinal bacterial overgrowth is defined by an abnormally elevated bacterial population within the small intestine. However, the mere presence of increased bacteria does not always equate to active disease. Clinical symptoms typically arise when inflammation is triggered by invasive bacterial strains.[7] These pathogenic bacteria can produce enzymes or endotoxins that damage the epithelial cell lining of the small intestine, leading to the characteristic symptoms of SIBO.[10] The bacterial species most frequently identified in SIBO include Escherichia coli, Aeromonas, and Klebsiella species.[11] Anaerobic bacteria can cause direct injury to the intestinal epithelium and produce enterotoxins, while aerobic bacteria primarily produce enterotoxins, both contributing to intestinal inflammation.[10] Bacterial overgrowth can also disrupt normal bowel motility, further exacerbating symptoms.

In SIBO, endoscopic and histopathological examination of the intestinal mucosa often reveals a seemingly healthy tissue appearance. However, nonspecific endoscopic findings may include mucosal edema, reduced vascularity, patchy areas of erythema (redness), or, in rare cases, ulceration.[12] Similarly, nonspecific histopathological findings can include villous blunting (flattening of the small intestinal villi), cryptitis (inflammation of the intestinal crypts), increased intraepithelial lymphocytes, and eosinophilia (increased eosinophils).[13]

Histopathology in SIBO

In most SIBO cases, both endoscopic evaluation and histopathologic examination of the small intestine and colon mucosa are within normal limits. When abnormalities are present, they are often nonspecific. Endoscopic findings can include mucosal edema, erythema, increased friability (easy bleeding) due to abnormal vascular patterns, and, infrequently, ulcerations.[12] Histological examination may reveal nonspecific findings such as villous blunting or atrophy, an increased number of intraepithelial lymphocytes, and eosinophilia.[14]

Toxicokinetics and SIBO

The symptoms of SIBO are largely a consequence of improper digestion and malabsorption within the small intestine. Fat malabsorption, resulting from bacterial deconjugation of bile acids, can lead to weight loss, diarrhea, and deficiencies in fat-soluble vitamins (A, D, and K).[15] Carbohydrate malabsorption contributes to abdominal distension (due to the production of hydrogen, carbon dioxide, and methane gases), excessive flatulence, and acidic stools.[16] Reduced nutrient uptake by the intestinal mucosa can also cause protein malabsorption. Interestingly, SIBO is generally associated with normal or even elevated folate levels, but decreased vitamin B12 levels. Vitamin B12 deficiency arises from damage to the ileal mucosa, affecting cobalamin binding sites. Deficiencies in vitamins B1 and B3 can occur due to bacterial overutilization of these nutrients.[17]

History and Physical Examination in SIBO

The clinical presentation of small intestinal bacterial overgrowth typically involves a combination of abdominal discomfort accompanied by bloating, flatulence, or chronic watery diarrhea. Steatorrhea (fatty stools) and weight loss due to fat malabsorption may also occur, particularly in individuals with altered gut anatomy, such as blind loop syndrome.[18] Vitamin deficiencies are a significant concern in SIBO, especially vitamin B12 deficiency, which can manifest as weakness, sensory ataxia (loss of coordination), and paresthesia (abnormal sensations like tingling or numbness). Severe vitamin D deficiency due to malabsorption can present with perioral numbness, hand and feet paresthesia, and muscle cramps resulting from hypocalcemia (low calcium levels).

D-lactic acidosis is a rare but serious neurological syndrome that can occur in SIBO, characterized by altered mental status, slurred speech, seizures, and ataxia. This syndrome is caused by bacterial fermentation of unabsorbed carbohydrates in the gut. Patients with SIBO associated with short bowel syndrome or jejunoileal bypass are at higher risk of developing D-lactic acidosis.[19] SIBO has also been implicated in the development of nonalcoholic fatty liver disease and hepatic encephalopathy.[20] Unless there is evidence of severe malnutrition, the physical examination in patients with SIBO is often unremarkable. In rare cases, a succussion splash (a splashing sound heard on abdominal auscultation) may be detected, indicating fluid-filled loops of bowel.

Evaluation and Diagnosis of SIBO

Currently, there is no universally accepted gold standard diagnostic test for SIBO.[2] When SIBO is suspected based on clinical signs and symptoms, diagnostic confirmation often relies on a positive carbohydrate breath test or, less commonly, a bacterial concentration exceeding 1000 colony-forming units/mL in a jejunal aspirate culture.[21]

The carbohydrate breath test is a non-invasive, rapid, and relatively inexpensive diagnostic tool.[22] This test is based on the principle that bacteria metabolizing carbohydrate substrates, such as lactulose or glucose, produce hydrogen or methane gas. These gases are then absorbed into the bloodstream and exhaled in the breath, where they can be measured.[21] A positive test is typically defined as a rise of more than 20 parts per million (ppm) above baseline in hydrogen within 90 minutes of carbohydrate ingestion, or a methane level exceeding 10 ppm.[21] It’s important to note that breath test results can be falsely positive in individuals with short bowel syndrome. Conversely, low counts of anaerobic organisms may lead to false negative results. A systematic review by Romagnuolo J et al. reported that the sensitivity of the glucose breath test ranges from 20% to 93%, and specificity from 45% to 86%.[23] The lactulose breath test has a reported sensitivity of 17% to 68% and specificity of 44% to 86%.[24] Despite these limitations, breath tests can be a useful diagnostic tool for SIBO in appropriate clinical settings, particularly when risk factors are absent.

Jejunal aspirate culture, while considered more direct, is an invasive, time-consuming, and costly procedure, as it requires an upper endoscopy to obtain a sample from the jejunum. A bacterial concentration of less than 10³ organisms per milliliter is generally considered diagnostic of SIBO. However, the results can be poorly reproducible and prone to false results due to patchy bacterial overgrowth within the small intestine or contamination of the sample with oropharyngeal flora during the procedure.[25] Other laboratory findings that may support a SIBO diagnosis include assessments of vitamin levels and markers of malnutrition.[18]

Once SIBO is suspected, further investigations to identify the underlying etiology are warranted. Anatomic and mucosal abnormalities can be evaluated using abdominal imaging techniques and endoscopies. Testing for underlying disorders affecting gastrointestinal motility, pancreatic insufficiency, and immunodeficiencies should be considered on a case-by-case basis.[3] In select cases, endoscopy with small bowel biopsy may be performed.

In patients without specific risk factors for SIBO, upper and lower endoscopies are often performed initially to exclude other conditions such as atrophic gastritis and Crohn’s disease. If endoscopies are normal, imaging studies may be conducted to rule out partial bowel obstruction, diverticula, fistulas, or other inflammatory processes. Magnetic resonance enterography can enhance the detection of small intestinal strictures but is a more expensive imaging modality.

A comprehensive evaluation to determine the underlying cause of SIBO is crucial, as SIBO is associated with various systemic conditions, including cirrhosis, kidney disease, chronic pancreatitis, and immunodeficiency disorders.[4] Other abnormal laboratory findings that may be observed in SIBO include macrocytic anemia, low vitamin B12, thiamine, and niacin levels, elevated folate and vitamin K levels, and increased fecal fat content. In rare instances, microcytic anemia or hypoalbuminemia may be reported.

Image alt text: Algorithm outlining the diagnostic approach for Small Intestinal Bacterial Overgrowth (SIBO), starting with clinical suspicion and progressing through breath tests and jejunal aspirate culture.

Treatment and Management of SIBO

The primary treatment strategy for SIBO involves antibiotic therapy to eradicate the bacterial overgrowth and nutritional repletion to address any identified deficiencies. Antibiotics commonly used in SIBO treatment include metronidazole, ciprofloxacin, tetracycline, amoxicillin-clavulanate, neomycin, and rifaximin, with rifaximin being the most extensively studied.[26] For patients with hydrogen-predominant SIBO, rifaximin at a dosage of 1650 mg/day for two weeks is considered an effective treatment option (Grade 2c recommendation).[26] In cases of methane-predominant SIBO, a combination therapy of neomycin at 1000 mg/day and rifaximin at 1650 mg/day for two weeks has shown effectiveness.[27] Concurrent vitamin and mineral deficiencies (such as vitamin B12, iron, thiamine, niacin, and other fat-soluble vitamins) should be addressed with appropriate supplementation.

Recurrence of SIBO following antibiotic treatment is observed in approximately 45% of patients. Recurrence rates tend to be higher in older adults, individuals who have undergone appendectomy, and those with chronic proton pump inhibitor (PPI) use.[28] For patients experiencing early recurrence (within three months), a second course of antibiotics is typically administered. In cases of late recurrence (beyond three months), antibiotic treatment is generally reserved for patients with positive carbohydrate breath test results. Recurrent SIBO can be treated effectively with either the same initial antibiotic or an alternative antibiotic.

An elemental diet can be considered for patients who are unable to tolerate antibiotics or who do not respond to antibiotic therapy after two courses. While limited observational studies suggest that elemental diets can induce remission of SIBO symptoms, their use is often limited by poor palatability and high cost. In one observational study, approximately 80% of patients achieved remission, defined as normalization of breath tests and resolution of symptoms, within two weeks of elemental diet therapy.[29]

Addressing the underlying cause of SIBO is essential for preventing recurrent episodes. Antibiotic prophylaxis (e.g., 5-10 days every two weeks or monthly) may be considered for patients experiencing frequent recurrences (more than 4 episodes per year). Antibiotics are generally rotated every two to three months in prophylactic regimens. SIBO-associated colitis and ileitis typically resolve with SIBO treatment. If severe symptoms persist despite SIBO treatment, further evaluation for inflammatory bowel disease (IBD) is warranted. If symptoms do not improve after two courses of antibiotic therapy, clinicians should consider alternative diagnoses.[30]

Probiotics, low fermentable oligo-, di-, and monosaccharide (FODMAP) diets, and statins have not been proven to be effective in resolving SIBO as standalone therapies. While some patients may experience symptomatic improvement with these approaches, they are not considered primary treatments for SIBO.

Differential Diagnosis of SIBO

When evaluating patients for small intestinal bacterial overgrowth, it is important to consider other conditions that can present with chronic diarrhea. Several diagnoses share overlapping symptoms with SIBO and should be included in the differential diagnosis. Irritable bowel syndrome (IBS), celiac disease (CD), and inflammatory bowel disease (IBD) are particularly relevant in this context. Irritable bowel syndrome is characterized by recurrent abdominal pain related to bowel movements and changes in stool frequency or consistency.[31] Celiac disease and SIBO can have similar clinical presentations; however, celiac disease is typically diagnosed based on positive celiac serologies and a negative carbohydrate breath test.[32] Both Crohn’s disease and SIBO can involve patchy mucosal inflammation. However, Crohn’s disease is further characterized by transmural inflammation and granulomas on biopsy, and may also involve perianal manifestations such as anal fissures and fistulas.[33]

Prognosis of SIBO

The prognosis for patients with small intestinal bacterial overgrowth largely depends on the nature and treatability of the underlying condition contributing to SIBO.[3] In most cases, the prognosis is favorable. SIBO rarely necessitates hospital admission and is not typically associated with severe complications.

Complications of Untreated SIBO

Severe and chronic small intestinal bacterial overgrowth can lead to significant weight loss and severe malnutrition, which can result in substantial morbidity and mortality. Early diagnosis and treatment of SIBO are crucial to address nutrient maldigestion and prevent malnourishment. If left untreated, SIBO can progress to intestinal failure.[34]

SIBO has been linked to increased ammonia production and may precipitate hepatic encephalopathy in individuals with pre-existing liver disease. SIBO associated with short bowel syndrome or jejunal bypass can lead to D-lactic acidosis, characterized by confusion and ataxia due to bacterial fermentation of unabsorbed carbohydrates.[19] The precise role of SIBO in non-alcoholic steatohepatitis (NASH) remains unclear, and further research is needed.

Consultations for SIBO

Patients presenting with unexplained chronic diarrhea or signs and symptoms suggestive of significant malnutrition should be referred to a gastroenterologist for further evaluation and management.

Deterrence and Patient Education for SIBO

For all patients diagnosed with small intestinal bacterial overgrowth, it is crucial to conduct further investigations to identify the underlying etiology and address it to prevent SIBO recurrence. Optimizing the management of conditions associated with abnormal intestinal motility, such as Crohn’s disease, irritable bowel syndrome, post-radiation enteropathy, diabetes mellitus, hypothyroidism, and scleroderma, is essential. Prokinetic medications may be beneficial as adjunctive therapy in these patients.[35] Opioids, which can decrease intestinal motility, and proton pump inhibitors (PPIs), which can reduce gastric acid production, should be used cautiously in individuals at risk for SIBO.[36] Surgical interventions may be considered in select patients with anatomical abnormalities contributing to recurrent SIBO.[35] The role of chronic antibiotic prophylaxis is limited, and probiotics have not been shown to be effective in SIBO prevention.[37] While challenging to adhere to strictly, an elemental diet may have a role in certain cases.[29]

Enhancing Healthcare Team Outcomes in SIBO Management

Small intestinal bacterial overgrowth is an often underdiagnosed condition with the potential for significant morbidity and mortality. Optimal management of SIBO requires a collaborative interprofessional healthcare team, including primary care physicians, gastroenterologists, surgeons, dietitians, pharmacists, and nurses. Early recognition of SIBO leads to more favorable outcomes and can prevent severe malnutrition. Once SIBO is diagnosed and antibiotic treatment is initiated, ongoing management should focus on addressing the underlying etiology to minimize the risk of recurrence.

Nursing plays a vital role in monitoring treatment effectiveness and patient progress during initial therapy, as well as ensuring patient adherence to treatment plans. Regular monitoring of calorie intake and weight assessments, both during and after treatment, is essential to ensure adequate nutritional recovery. Nurses should promptly report any concerns or changes in patient status to the treating clinician. Pharmacists contribute to optimal SIBO management by assisting with antibiotic selection, verifying appropriate dosing, and performing medication reconciliation. Pharmacists also play a crucial role in identifying and addressing potential drug-condition interactions, particularly concerning opioids and PPIs. Effective SIBO management necessitates a coordinated interprofessional team approach, with physicians, specialists, specialty-trained nurses, and pharmacists collaborating across disciplines to achieve the best possible patient outcomes. [Level 5 evidence] The overall prognosis is heavily influenced by the successful management of the underlying condition. If the underlying etiology remains unaddressed, the long-term prognosis may be less favorable.[3] [Level 2 evidence]

Review Questions

(Note: Review questions are present in the original article but are not included in this rewritten version as per instructions.)

References

(Note: The reference list from the original article is retained below for completeness and academic integrity.)

1. Rao SSC, Bhagatwala J. Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management. Clin Transl Gastroenterol. 2019 Oct;10(10):e00078. [PMC free article: PMC6884350] [PubMed: 31584459]
2. Khoshini R, Dai SC, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci. 2008 Jun;53(6):1443-54. [PubMed: 17990113]
3. Bures J, Cyrany J, Kohoutova D, Förstl M, Rejchrt S, Kvetina J, Vorisek V, Kopacova M. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010 Jun 28;16(24):2978-90. [PMC free article: PMC2890937] [PubMed: 20572300]
4. Vantrappen G, Janssens J, Hellemans J, Ghoos Y. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977 Jun;59(6):1158-66. [PMC free article: PMC372329] [PubMed: 864008]
5. Roland BC, Ciarleglio MM, Clarke JO, Semler JR, Tomakin E, Mullin GE, Pasricha PJ. Low ileocecal valve pressure is significantly associated with small intestinal bacterial overgrowth (SIBO). Dig Dis Sci. 2014 Jun;59(6):1269-77. [PubMed: 24795035]
6. Riordan SM, McIver CJ, Wakefield D, Duncombe VM, Thomas MC, Bolin TD. Small intestinal mucosal immunity and morphometry in luminal overgrowth of indigenous gut flora. Am J Gastroenterol. 2001 Feb;96(2):494-500. [PubMed: 11232696]
7. Jones RM, Neish AS. Recognition of bacterial pathogens and mucosal immunity. Cell Microbiol. 2011 May;13(5):670-6. [PubMed: 21352463]
8. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr. 1999 May;69(5):1035S-1045S. [PubMed: 10232646]
9. Choung RS, Ruff KC, Malhotra A, Herrick L, Locke GR, Harmsen WS, Zinsmeister AR, Talley NJ, Saito YA. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther. 2011 May;33(9):1059-67. [PubMed: 21395630]
10. Kirsch M. Bacterial overgrowth. Am J Gastroenterol. 1990 Mar;85(3):231-7. [PubMed: 2178395]
11. Bouhnik Y, Alain S, Attar A, Flourié B, Raskine L, Sanson-Le Pors MJ, Rambaud JC. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol. 1999 May;94(5):1327-31. [PubMed: 10235214]
12. Hoog CM, Lindberg G, Sjoqvist U. Findings in patients with chronic intestinal dysmotility investigated by capsule endoscopy. BMC Gastroenterol. 2007 Jul 18;7:29. [PMC free article: PMC1940016] [PubMed: 17640373]
13. Greenson JK. The biopsy pathology of non-coeliac enteropathy. Histopathology. 2015 Jan;66(1):29-36. [PubMed: 25234408]
14. Klaus J, Spaniol U, Adler G, Mason RA, Reinshagen M, von Tirpitz C C. Small intestinal bacterial overgrowth mimicking acute flare as a pitfall in patients with Crohn’s Disease. BMC Gastroenterol. 2009 Jul 30;9:61. [PMC free article: PMC2728727] [PubMed: 19643023]
15. Shindo K, Machida M, Koide K, Fukumura M, Yamazaki R. Deconjugation ability of bacteria isolated from the jejunal fluid of patients with progressive systemic sclerosis and its gastric pH. Hepatogastroenterology. 1998 Sep-Oct;45(23):1643-50. [PubMed: 9840121]
16. Pai RK. A practical approach to small bowel biopsy interpretation: celiac disease and its mimics. Semin Diagn Pathol. 2014 Mar;31(2):124-36. [PubMed: 24815938]
17. Lakhani SV, Shah HN, Alexander K, Finelli FC, Kirkpatrick JR, Koch TR. Small intestinal bacterial overgrowth and thiamine deficiency after Roux-en-Y gastric bypass surgery in obese patients. Nutr Res. 2008 May;28(5):293-8. [PubMed: 19083422]
18. Quigley EM, Abu-Shanab A. Small intestinal bacterial overgrowth. Infect Dis Clin North Am. 2010 Dec;24(4):943-59, viii-ix. [PubMed: 20937459]
19. Bongaerts GP, Tolboom JJ, Naber AH, Sperl WJ, Severijnen RS, Bakkeren JA, Willems JL. Role of bacteria in the pathogenesis of short bowel syndrome-associated D-lactic acidemia. Microb Pathog. 1997 May;22(5):285-93. [PubMed: 9160298]
20. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014 May;146(6):1513-24. [PMC free article: PMC3996054] [PubMed: 24440671]
21. Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Schmulson M, Valdovinos M, Zakko S, Pimentel M. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol. 2017 May;112(5):775-784. [PMC free article: PMC5418558] [PubMed: 28323273]
22. Ghoshal UC, Ghoshal U, Das K, Misra A. Utility of hydrogen breath tests in diagnosis of small intestinal bacterial overgrowth in malabsorption syndrome and its relationship with oro-cecal transit time. Indian J Gastroenterol. 2006 Jan-Feb;25(1):6-10. [PubMed: 16567886]
23. Romagnuolo J, Schiller D, Bailey RJ. Using breath tests wisely in a gastroenterology practice: an evidence-based review of indications and pitfalls in interpretation. Am J Gastroenterol. 2002 May;97(5):1113-26. [PubMed: 12014715]
24. King CE, Toskes PP. Comparison of the 1-gram [14C]xylose, 10-gram lactulose-H2, and 80-gram glucose-H2 breath tests in patients with small intestine bacterial overgrowth. Gastroenterology. 1986 Dec;91(6):1447-51. [PubMed: 3770368]
25. Corazza GR, Menozzi MG, Strocchi A, Rasciti L, Vaira D, Lecchini R, Avanzini P, Chezzi C, Gasbarrini G. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology. 1990 Feb;98(2):302-9. [PubMed: 2295385]
26. Shah SC, Day LW, Somsouk M, Sewell JL. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013 Oct;38(8):925-34. [PMC free article: PMC3819138] [PubMed: 24004101]
27. Pimentel M, Chang C, Chua KS, Mirocha J, DiBaise J, Rao S, Amichai M. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci. 2014 Jun;59(6):1278-85. [PubMed: 24788320]
28. Lauritano EC, Gabrielli M, Scarpellini E, Lupascu A, Novi M, Sottili S, Vitale G, Cesario V, Serricchio M, Cammarota G, Gasbarrini G, Gasbarrini A. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol. 2008 Aug;103(8):2031-5. [PubMed: 18802998]
29. Pimentel M, Constantino T, Kong Y, Bajwa M, Rezaei A, Park S. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci. 2004 Jan;49(1):73-7. [PubMed: 14992438]
30. Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, Paterson C, Bortey E, Forbes WP. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology. 2016 Dec;151(6):1113-1121. [PubMed: 27528177]
31. Ghoshal UC, Shukla R, Ghoshal U. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut Liver. 2017 Mar 15;11(2):196-208. [PMC free article: PMC5347643] [PubMed: 28274108]
32. Losurdo G, Marra A, Shahini E, Girardi B, Giorgio F, Amoruso A, Pisani A, Piscitelli D, Barone M, Principi M, Di Leo A, Ierardi E. Small intestinal bacterial overgrowth and celiac disease: A systematic review with pooled-data analysis. Neurogastroenterol Motil. 2017 Jun;29(6) [PubMed: 28191721]
33. Shah A, Morrison M, Burger D, Martin N, Rich J, Jones M, Koloski N, Walker MM, Talley NJ, Holtmann GJ. Systematic review with meta-analysis: the prevalence of small intestinal bacterial overgrowth in inflammatory bowel disease. Aliment Pharmacol Ther. 2019 Mar;49(6):624-635. [PubMed: 30735254]
34. Ziegler TR, Cole CR. Small bowel bacterial overgrowth in adults: a potential contributor to intestinal failure. Curr Gastroenterol Rep. 2007 Dec;9(6):463-7. [PubMed: 18377796]
35. Bohm M, Siwiec RM, Wo JM. Diagnosis and management of small intestinal bacterial overgrowth. Nutr Clin Pract. 2013 Jun;28(3):289-99. [PubMed: 23614961]
36. Compare D, Pica L, Rocco A, De Giorgi F, Cuomo R, Sarnelli G, Romano M, Nardone G. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest. 2011 Apr;41(4):380-6. [PubMed: 21128930]
37. Zhong C, Qu C, Wang B, Liang S, Zeng B. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence. J Clin Gastroenterol. 2017 Apr;51(4):300-311.